There are 2867 resources available
1763P - Real-world outcomes before and after the access to immune-checkpoint inhibitors (ICI) in advanced urothelial carcinoma (aUC)
Presenter: Jose Tapia
Session: Poster session 18
1764P - The vanishing clinical value of PD-L1 status as predictive biomarker in first-line treatment of urothelial carcinoma of the bladder
Presenter: Alexander Tamalunas
Session: Poster session 18
1765P - Undertreatment rates, associated factors, and survival among patients with locally advanced or metastatic urothelial cancer (la/mUC): A systematic literature review
Presenter: Thomas Wilke
Session: Poster session 18
1766P - Urachal cancer: A population-based study of 315 cases in California from 1988-2019
Presenter: David Benjamin
Session: Poster session 18
1767P - Outcomes after first line therapy in metastatic bladder and upper tract cancer
Presenter: Luke Furtado O'Mahony
Session: Poster session 18
1768P - Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC)
Presenter: Bernadett Szabados
Session: Poster session 18
1769P - KDM6A mutation act as a potential immunotherapy biomarker in urothelial carcinoma
Presenter: Wenjing Xiao
Session: Poster session 18
1770P - Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)
Presenter: Chantal Stockem
Session: Poster session 18
1771P - Genomic characteristics and clinical outcomes of HRAS-mutated urothelial bladder cancer
Presenter: Jesus Antonio Ocejo Gallegos
Session: Poster session 18
1772P - Characterisation of a DNA repair deficiency (DRD) biomarker phenotype in metastatic urothelial carcinoma (mUC) within the ATLANTIS clinical trial platform
Presenter: Simon Crabb
Session: Poster session 18